December 8, 2023
Sosei Group said on December 7 that Pivlaz (clazosentan) has won regulatory approval in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing. The approval, granted to Idorsia...read more